Filing Flows › Ionis Pharmaceuticals (IONS) › Stock forecast & fair value
Ionis Pharmaceuticals (IONS) stock forecast and fair value
Ionis Pharmaceuticals (IONS) trades at $42.94. 23 analysts' median price target is $85.00 (+98%), from $58.00 to $105.00. Across 10 valuation methods the middle fair value is $25.86 (-40%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/Sales vs peers | $17.60 | $26.20 | $47.34 | -39% |
| EV/Sales vs peers, weighted | $22.78 | $34.43 | $51.12 | -20% |
| Residual income | −$2.14 | −$2.18 | −$2.21 | -105% |
| Analysts' price targets | $58.00 | $84.13 | $105.00 | +96% |
| Tangible book (asset value) | $2.13 | $2.66 | $2.66 | -94% |
| Survival-weighted value | $17.38 | $25.86 | $46.70 | -40% |
| Stage-weighted value (decline / turnaround) | $11.35 | $16.69 | $29.30 | -61% |
| Combined forecast (3 months) | $35.16 | $44.65 | $55.32 | +4% |
| Schwartz–Moon simulation (cash can run out) | $0.00 | $10.34 | $29.34 | -76% |
| EV/Sales fair multiple (multi-factor fit) | $10.58 | $16.35 | $28.71 | -62% |
Ionis Pharmaceuticals' latest quarter
Ionis Pharmaceuticals, Q2 2026: revenue $268M (-41% year over year), operating margin -38.2%, net loss $115M, operating cash flow $566M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for IONS stock?
The median of 23 analysts' 12-month targets is $85.00, +98% from $42.94; the range is $58.00 to $105.00. The average rating is buy.
What is Ionis Pharmaceuticals' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between −$2.18 and $84.13, with a middle value of $25.86 against a price of $42.94. Each method's assumptions are on the page.
Does Ionis Pharmaceuticals usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is IONS stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.